余自成,高瑜,田薇薇,瞿江媛,马明华,陈红君,王艳霞,陈红专

• 1:上海市杨浦区中心医院临床药学和药理学研究室
• 2:上海交通大学医学院药理学教研室

摘要(Abstract)：

目的建立Caco-2细胞单层模型用于药物转运研究。方法按照常规的细胞培养方法,将Caco-2细胞接种到Millicell小室内(接种密度1×10~6个·mL~(-1)),培养21 d。定期用细胞电位仪监测跨上皮细胞电阻(TEER),评价细胞单层的紧密性与完整性;通过荧光黄转运实验检查Caco-2细胞单层模型细胞旁路转运通透性;通过普萘洛尔转运实验验证Caco-2细胞单层模型跨细胞被动转运通透性。结果培养21 d后,TEER值达到(981±123)Ω·cm~2,荧光黄和普萘洛尔的表观通透系数分别为0.33×10及16.7×10~(-6)cm·s~(-1)。结论本研究建立的Caco-2细胞单层模型紧密、完整,具有良好通透性,可用于药物转运研究。

关键词(KeyWords)： Caco-2细胞单层;肠道转运模型;跨上皮细胞电阻

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 余自成,高瑜,田薇薇,瞿江媛,马明华,陈红君,王艳霞,陈红专

DOI: 10.19577/j.cnki.issn10074406.2012.04.005

参考文献(References)：

• [1]ShiyinYee.In atro penneability across Caco-2 cell(Colonic) can pre- dict in vivo(small intestinal)absorption in man-fact or myth[J].Pharm Res,1997,14(6):763.
• [2]Crivori P,Reinach B,Pezzetta D,et al.Computational models for identifying potential P-glycoprotein substrates and inhibitars[J].Mol Pharm, 2006,3(1):33.
• [3]Shirasaka Y,Kawasaki M,Sakane T,et al.Induction of human P-glycoprotein in Caco-2 cells:development of a highly sensitive assay system for P-glycoprotein- mediated drug transport[J].Drug Metab Pharma-cokinet, 2006,21(5):414.
• [4]Madgula VL,Avula B,Choi YW,et al.Transport of Schisandra chinensis extract and its biologically-active constituents across Caco-2 cell monolayers - an in-vitro model of intestinal transport[J].J Pharm Pharmacol, 2008,60(3):363.
• [5]Press B,Di Grandi D.Permeability for intestinal absorption:Caco-2 assay and related issues[J].Curr Drug Metab,2008,9(9):893.
• [6]Doi N,Tomita M,Hayashi M.Absorption enhancement effect of acylcamitines through changes in tight junction protein in Caco-2 cell monolayers [J].Drug Metab Pharmacokinet,2011,26(2):162.
• [7]Brand W,van der Wei PA,Rein MJ,et al.Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers[J].Drug Metab Dispos,2008,36(9):1794.
• [8]FJsbyR,Surry DD,Smith VN,etal.Validation and application of Caco -2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions [J].Xenobiotica,2008,38(7-8):1140.
• [9]Eberl S,Renner B,Neubert A,et al.Role of P-glycoprotein inhibition for drug interactions:evidence from in vitro and pharmacoepi-demiological srudies[J].Clin Pharmacokinet,2007,46(12):1039.
• [10]Yan F,Jiang Y,Li YM,et al.Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 isomers,tetrataiso -hydroquinolin derivatives[J]. Biol Pharm Bull,2008,31(6):1258.
• [11]Fenner KS,Troutman MD,Kempshall S,et al.Drug-drug interactions mediated through P-glycoprotein:clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug[J].Clin Pharmacol Ther, 2009,85(2):173.
• [12]PolliJW,Wring SA,Humphreys JE,et al.Rational use of in vitro Pglycoprotein assays in drug discovery[J].J Pharmacol Exp Ther, 2001,299(2):620.
• [13]马燕,李沛波,苏薇薇,等.药理实验中Caco-2细胞模型建立的评价指标[J].中药材,2006,29(9):946.
• [14]孙敏捷,盛星,胡一桥.Caco-2细胞单层模型的建立与验证[J].中国药学杂志,2006,41(18):1431.
• [15]Ranaldi G,Consalvo R,Sambuy Y,et al.Permeability characteristics of parental and clonal human intestinal Caco-2 cell lines differentiated in serum supplemented and serum-free media[J].Toxicol In Vitro, 2003,17(5-6):761.
• [16]Wang Q,Strab R,Kardos P,et al.Application and limitation of inhibitors in drug-transporter interactions studies[J].Int J Pharm,2008, 356(1-2):12.